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O�jectives: Hi�� doses o� c�e�ot�erapy �enerate ��� da�a�e in patients under�oin� �one �arrow transplan-
tation (BMT)� due to t�e production o� reactive oxy�en species (ROS).  In order to evaluate t�e local de�ensive 
e��ectiveness o� t�e patient under�oin� BMT� t�e concentrations o� t�e antioxidants superoxide dis�utase (SO�) 
and uric acid (U�) were �easured in saliva. 
Study �esi�n: Basal saliva sa�ples were collected �ro� 20 patients under�oin� BMT at t�e Oncolo�y �epart-
�ent� Sanatorio �llende (C�rdo�a)� in t�e sta�es: initial� prior to conditionin� t�erapy (I); �iddle: 7 to 10 days 
after BMT (M) and final stage, 30 days after discharge from isolation (F). SOD levels were determined using a 
R���OX kit (R��SO� superoxide dis�utase �anual)� and �or uric acid enzy�atic UO� / P�P spectrop�oto-
�etric �et�od� ( Trinder Color Kit � Wiener La�) was used.
Results: 85% of the patients developed oral mucositis. SOD concentration in the M stage was significantly higher 
(p<0.01) compared with stage I, and it reversed in stage F. UA concentration was significantly lower (p<0.001) in 
sta�e M co�pared wit� sta�e I� and in sta�e � it recovered t�e initial values.
Conclusions: SO� increase in sta�e M coincided wit� t�e appearance o� �ucositis� w�ic� could �e interpreted as a 
de�ensive �ec�anis� o� saliva a�ainst oxidative stress produced �y c�e�ot�erapy. U� decrease in sta�e M would 
�avour t�e develop�ent o� �i��er de�rees o� �ucositis.
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Introduction 
Hi��ly i��unosuppressive and toxic treat�ents prior 
to t�e �one �arrow ste� cells transplantation (BMT) 
�enerate reactive oxy�en species (ROS)� w�ic� da�a�e 
t�e ��� o� t�e oral epit�eliu� and su��ucosa.
T�is da�a�e �enerates clinical and �istolo�ical altera-
tions in oral �ucosa and periodontal tissues� as well as 
dys�unctions in t�e salivary �lands and c�an�es in sa-
liva (1).
T�e current literature s�ows isolated and controversial 
results related to t�e side e��ects o� di��erent oncolo�ic 
dru�s on t�e oral cavity (2).
Likewise� t�e de�ree o� incidence and severity o� t�e 
complications is not clear, which makes difficult to con-
solidate palliative supportive treat�ents o� t�e da�a�e. 
Most o� t�e antineoplastic dru�s act indiscri�inately on 
t�e �asal cells o� oral epit�eliu�� alterin� its renewal 
capacity. T�is� leads to t�e appearance o� a series o� sys-
te�ic and local side e��ects suc� as �ucositis� xerosto-
�ia� in�ections and �e�orr�a�e. 
Mucositis is an inflammatory reaction that may affect 
all t�e �astrointestinal �ucosa� wit� �i�� prevalence in 
t�e orop�aryn�eal area (3-6). 
Mucositis is associated with a significant increase in the 
�or�idity� producin� a delay or even t�e interruption o� 
t�e antineoplastic treat�ent as well as an increase in t�e 
t�erapeutic costs (7�8).  
T�e etiopat�o�enesis o� oral �ucositis is not totally clear. 
However� series o� risk �actors associated wit� its ap-
pearance �ave �een descri�ed� w�ic� are related �ainly 
wit� t�e type o� oncolo�ical treat�ent and wit� patient 
individual �actors. In patients under�oin� c�e�ot�erapy� 
t�e incidence and severity o� toxic �ucositis could �e 
deter�ined �y t�e dose and t�e sc�e�e o� ad�inistra-
tion.  �or�ally appears 3 to 5 days a�ter t�erapy �as �een 
started� it reac�es a �axi�u� �etween 7 to 10 days� and 
resolves in t�e �ollowin� 5 to 7 days� unless it is co�pli-
cated �y in�ection or �e�orr�a�e (9�10). 
Clinical si�ns o� �ucositis include epit�elial atrop�y� ero-
sions and ulcerations o� t�e oral �ucosa� w�ic� increases 
t�e risk o� syste�ic in�ection. Pain is o�ten intense and 
could inter�ere wit� �asic oral �unctions suc� as p�ona-
tion� swallowin� and eatin� (11)� and in so�e cases it re-
quires t�e ad�inistration o� opioid anal�esics.
I��unosuppression induced �y c�e�ot�erapy durin� 
t�e conditionin� period prior to �one �arrow trans-
plantation secondarily alters t�e capacity to respond to 
anti�enic sti�uli. T�e severity o� t�e �ucositis in t�ese 
patients could �e related wit� t�e de�ree o� i��unosup-
pression. 
Reco�nizin� t�e need to develop �ore e��ective and 
�iolo�ical �ased t�erapies� recent researc� �as �ocused 
on t�e pat�o�iolo�y o� �ucositis. In its initial p�ase it 
involves direct da�a�e to ��� and ot�er cell co�po-
nents� �eneratin� ROS� w�ic� causes a cascade o� �io-
lo�ical events. In order to neutralize t�e�� t�e or�anis� 
�as power�ul antioxidant syste�s� �ot� enzy�atic and 
non-enzy�atic (12). 
T�e de�ensive �attery provided �y saliva is �ade o� 
i��unoenzy�atic a�ents suc� as lysozy�e� I� �� 
salivary a�ylase and antioxidant su�strates wit� a 
certain catalytic e��ect suc� as peroxidase� Superoxide 
�is�utase (SO�) and  Uric �cid (U�) responsi�le �or 
70% o� t�e antioxidant potential o� saliva. T�e pres-
ence o� eac� one o� t�ese antioxidants in saliva is con-
ditioned �ainly �y �landular production� especially 
t�at o� t�e parotid �land as in t�e case o� SO�. T�e 
verification carried out by Kohen in 1992, that saliva 
modifies its enzymatic profile according to the humor 
reducin� needs  under t�e circu�stances o� oxidative 
stress, modified the then prevailing idea that it is a liq-
uid of stable composition (13). Inflammatory responses 
provide a �u�e a�ount o� �ree radicals� especially su-
peroxide anion and H2O2. T�e salivary enzy�atic pro-
duction o� antioxidants is e�inently o� �landular ori-
�in� �ein� suscepti�le o� increasin� its concentration 
in di��erent types o� inflammatory disorders (14,15). 
The identification of antioxidants in tissues, blood and 
saliva provides an idea o� t�e e��ective local or sys-
te�ic de�ensive syste�s.
Based on t�ese antecedents� t�e ai� o� our work was 
to evaluate t�e e��ective local de�ense o� patients wit� 
�ucositis under�oin� BMT �y �easurin� salivary anti-
oxidants suc� as SO� and U�. 
Material and Methods 
� lon�itudinal o�servational study was carried out� in a 
population o� 20 patients ad�itted to t�e �epart�ent o� 
Oncolo�y� Sanatorio �llende� durin� 2009-2012� wit� 
prescription o� BMT.
Exclusion criteria �or t�is study were: patients under 
t�e a�e o� 18 and over t�e a�e o� 80� pre�nant patients� 
patients wit� previous radiot�erapy w�ic� �ad a��ected 
t�e cranio�acial area� and tu�ors in t�e �ead and neck. 
In�or�ed consent was o�tained �ro� eac� participant� 
t�e study was approved �y t�e Medical Et�ics Co��it-
tee o� Sanatorio �llende and it was inscri�ed in REPIS 
(Provincial Re�ister o� Researc� on Hu�an Healt�) un-
der nu��er 1189 (15/04/09).
-T�e �ollowin� oral �ealt� indexes were re�istered: 
Plaque index ai�ed at quanti�yin� plaque deposits in 
t�e �in�ival �ar�in (16).
Löe and Silness index: to evaluate t�e de�ree o� �in�i-
val inflammation (17).  
Simplified hemorrhage index: It indicates positive or 
ne�ative �leedin�� a�ter pro�in� t�e �in�ival sulcus 
wit� a periodontal pro�e (18).
Sulcus dept� index (<4�� deep) or pocket (= > 4�� 
deep) o� vesti�ular sur�ace o� t�e dental ele�ents in 
�ot� arc�es. 
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-Sto�atolo�ical exa�ination and saliva collection  
T�e sto�atolo�ical exa�ination and t�e collection o� 
saliva sa�ples were carried out at t�e �ollowin� ti�es: 
�) Initial sta�e: prior to c�e�ot�erapy
B) Middle sta�e: durin� t�e isolation period� �etween 
t�e sevent� and tent� day a�ter BMT.
C) Final stage: Thirty days after finishing the isolation 
period. 
Sto�atolo�ical exa�ination: an exa�ination o� t�e so�t 
tissues o� t�e oral cavity and annexed structures was 
�ade. T�e sto�atolo�ical lesions were se�io�rap�ed 
and an icono�rap�y o� t�e� was �ade. 
�ia�nostic and c�aracterization o� �ucositis was per-
�or�ed �ollowin� t�e WHO scale (19).  
-Collection o� �asal saliva: 
Patients in a fasting state or at the first or second hour 
a�ter �reak�ast� restin�� sittin� and silent� were asked to 
was� t�eir �out� wit� distilled water. �or 5 �inutes� 
t�e saliva t�at �or�ed and accu�ulated in t�e �out� 
was collected in a disposa�le centri�u�al conic plastic 
tu�e previously wei��ted. Every patient prior to t�e 
BMT was considered as control �roup.
T�e �aterial o�tained was carried in a �er�etically 
sealed container wit� �reezin� �el� at -4 C º. T�en it was 
wei��ted� centri�u�ed� its pH was deter�ined and it 
was conserved at - 18 Cº �or its su�sequent �ioc�e�ical 
analysis (20). 
-Sa�ple analysis: 
T�ese were processed and analyzed at t�e la�oratory o� 
t�e P�ysiolo�y C�air� Odontolo�y �aculty� U.�.C.
In order to deter�ine SO�� a R���OX kit was used 
(R��SO� Superoxide �is�utases Manual)� and �or 
U� an enzy�atic UO� / P�P spectrop�oto�etric �e-
t�od (Trinder Color Kit � Wiener La�) was used.
Statistical �nalysis: data were analyzed �y Student �T� test 
�or paired data to co�pare t�e di��erent sta�es o� treat�ent� 
settin� a P value < 0.05 for statistical significance.  
Results
65% O� t�e patients included in t�e sa�ple were �e-
�ales. Patients were �etween 27 and 71 years- old� wit� 
a �ean a�e o� 44 years- old. Ot�er c�aracteristics o� t�e 
patients included in t�e sa�ple are s�own in ta�le 1.
85% o� t�e patients o�served developed oral �ucosi-
tis. In relation to t�e de�ree o� severity� 50% s�owed 
�ucositis �rade 1� 15.78% �rade 2 and 15�78% �rade 3� 
w�ile 5.26% s�owed �rade 4.
The samples of basal saliva analyzed showed a signifi-
cant increase o� SO� durin� t�e �iddle sta�e� 2.25 U/
ml ± 1.30 compared to initial 0.73 U/ml ± 0.42 and final 
1.67 U/�l ± 0.94 (p<0.01) sta�es (�i�. 1).
UA showed a significant decrease in the middle stage 
1.17 ��/dl ± 0.22 co�pared to t�e initial 2.28 ��/dl 
± 0.5 and final 1.58 mg/dl ± 0.33 stages respectively 
(p<0.001) (�i�. 2).  
Oral �ealt� indexes yielded t�e �ollowin� results: 
Gingival inflammatory response, evaluated by Löe and 
Silness rates� increased in t�e �iddle co�pared to t�e 
initial sta�e (p< 0.01), and reverted by the final stage. 
The simplified bleeding index did not exhibit statistically 
significant changes and plaque index revealed an increase 
in t�e �iddle sta�e co�pared wit� t�e initial sta�e. 
�ept� index o� t�e vesti�ular sulcus o� anterior and 
posterior elements significantly increased in the middle 
p�ase �ut did not revert at t�e end o� t�e treat�ent (p 
<0.01).
Discussion
The identification of antioxidants in tissues, blood and sa-
liva and other body fluids provides an idea of the local or 
syste�ic de�ensive e��ectiveness o� t�e individual (21).
In t�is sense� �a�ler et al. state t�at saliva constitutes an 
i�portant de�ensive line a�ainst oxidative stress (22). 
Ki� et al. classi�y t�e salivary antioxidants in t�ree 
large groups, according to their function. The first 
�roup is �or�ed �y preventive antioxidants� w�ic� are 
t�ose w�ic� in�i�it t�e production o� �ree radicals� suc� 
as SO�� carotenoids� catalase� �lutat�ione peroxidase� 
transferrin, albumin and haptoglobin. Secondly, we find 
�sweepin�� antioxidants� suc� as vita�in � and E� U�� 
al�u�in and �iliru�in� w�ic� eli�inate �ree radicals in 
order to in�i�it t�e startin� and spreadin� o� cell da�-
a�e. �inally� enzy�es suc� as proteases� trans�erase� 
lipases� etc� repair t�e da�a�e caused in t�e tissues (23-
24).
�a�ler et al. consider t�at t�e antioxidant salivary sys-
te� is �or�ed �y an enzy�atic co�ponent� w�ere t�e 
�ain exponent is SO� and a non-enzy�atic co�po-
nent� represented �ainly �y U�.
T�e production o� SO� in saliva is o� �landular ori�in� 
�ainly parotideal. Ya�a�oto et al. s�owed t�at t�is 
enzy�e is capa�le o� increasin� in response to di��er-
ent inflammatory reactions. In fact, some studies have 
de�onstrated an increase in t�e concentration o� SO� 
in processes suc� as tonsillitis� pulpitis� periodontitis 
and peri-i�plantitis (25-27).
T�ere are �ew studies corcernin� t�e relations�ip �e-
tween SOD and inflammation in the oral cavity or peri-
odontium, and the results are conflicting. Ellis et al. 
state that a significative reduction of SOD activity was 
�ound in �in�ival tissue adjacent to deep periodontal 
pockets (28�29). Ot�er studies �ad indicated t�at total 
salivary antioxidants activity re�ains at t�e sa�e level 
in periodontal disease� or is reduced (30�31). Canakci et 
al. �ad de�onstrated t�at SO� activity �ot� in saliva 
was lower in patients wit� periodontal disease co�-
pared to �ealt�y su�jects (32).
On t�e ot�er �and� Wei et al. stated that SOD was signifi-
cantly �i��er in t�e c�ronic periodontitis patients co�-
pared to t�e �ealt�y patients o� t�e control �roup (33).  
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Nagler studied the antioxidant profile of human saliva 
in �ealt�y adults and deter�ined t�at nor�al SO� va-
lues are 0.79 U/�l �or �asal saliva y 0.80 U/�l �or t�e 
sti�ulated one. In our work on oncolo�ic patients� we 
observed a significant increase in the identifications 
o� SO� durin� t�e �iddle sta�e� coincidin� wit� t�e 
�e�innin� o� clinical �ani�estations o� oral �ucositis. 
T�is increase in t�e concentration o� SO� could �e in-
terpreted as a de�ense �ec�anis� o� saliva a�ainst oxi-
dative stress produced �y c�e�ot�erapy at �i�� doses 
e�ployed durin� t�e conditionin� sta�e prior to �one 
�arrow transplantation.
Considerin� t�e results o� ot�er �roups as we discussed 
a�ove� we consider t�at t�is increased activity o� SO�� 
at least in part� also �ay �e due to t�e c�an�es in peri-
odontal indexes durin� t�e �iddle sta�e. However� re-
Patient Sex Age Pathology Therapeutic Scheme 
1 Male 53 Multiple Myelo�a Mel�alan 
2 Male 57 �cute Myeloid Leuke�ia Busulp�anCyclop�osp�a�ide 
3 �e�ale 30 �on-Hod�kin´S Ly�p�o�a 
Car�ustine 
Etoposide
�ra-C � Cyclop�osp�a�ide 
4 �e�ale 56 �on-Hod�kin´S Ly�p�o�a 
Car�ustine 
Etoposide
�ra-C � Cyclop�osp�a�ide 
5 Male 54 �on-Hod�kin´S Ly�p�o�a �ra-C Cyclop�osp�a�ide 
6 Male 42 Hod�kin´S Ly�p�o�a �ra-CCyclop�osp�a�ide 










9 �e�ale 58 Multiple Myelo�a Melp�alan 
10 �e�ale 40 Multiple Myelo�a Melp�alan 
11 Male 61 Multiple Myelo�a Melp�alan 





13 Male 27 Hod�kin´S Ly�p�o�a 
Car�ustine 
Etoposide
�ra-C � Cyclop�osp�a�ide 




15 �e�ale 33 Hod�kin´S Ly�p�o�a Busulp�anCyclop�osp�a�ide 
16 �e�ale 28 Hod�kin´S Ly�p�o�a EtoposideCitara�ine 
17 �e�ale 45 Hod�kin´S Ly�p�o�a Busulp�anCyclop�osp�a�ide 





19 �e�ale 36 Hod�kin´S Ly�p�o�a Cyclop�osp�a�ide Busulp�an
20 �e�ale 56 �cute Myeloid Leuke�ia Busulp�anCyclop�osp�a�ide 
Table 1. C�aracteristics o� patients o� t�e sa�ple.
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ports on t�e relations�ip �etween t�e antioxidant status 
and periodontal diseases �ave �een controversial. We 
consider t�at �urt�er investi�ation is needed in order to 
clari�y possi�le correlation �etween salivary SO� le-
vels� �rades o� �ucositis and periodontal status.   
On t�e ot�er �and� Halliwell and Moore reported t�at 
t�e �ost i�portant antioxidant o� saliva is U�� respon-
si�le �or 70% o� t�e antioxidant activity� �ollowed �y 
al�u�in and ascor�ic acid (27�31). 
Goll and Mookerjee o�served t�at t�e concentrations 
of this antioxidant in total saliva correlate significantly 
wit� t�ose o� plas�a (34).
�a�ler reported t�at t�e nor�al values o� U� were: 2.87 
��/dl in �asal saliva and 10.5 ��/dl �or sti�ulated sa-
liva. In our study we observed a significant decrease of 
U� durin� t�e �iddle sta�e� w�ic� could �avor t�e ap-
pearance and pro�ression o� oral �ucositis. 
�ccordin� to Bi�i et al.� an increase in t�e production 
o� salivary SO� could �e considered a partial co�pen-
satory response w�en t�ere is reduction o� t�e concen-
trations o� U� and oxidative stress in t�e oral cavity 
(35). �s re�ards t�is� our results coincide wit� t�e a�ove 
�entioned since t�ey s�ow an increase in t�e concen-
tration o� SO� acco�panied �y a decrease o� t�e con-
centrations o� U� durin� t�e �iddle sta�e (36-37).
I�paired oxidant/antioxidant �alance is responsi�le �or 
t�e tissue da�a�e in BMT patients. Measurin� so�e 
para�eters suc� as salival SO� and U�� would allow 
to i�prove noninvasive �et�ods in order to evaluate 
t�e antioxidant capacity in patients under�oin� BMT. 
We propose t�at �uture studies on t�is issue s�ould �e 
done. T�e results o� t�e present work �ay �e use�ul in 
evaluating the antioxidant profile during conditioning 
c�e�ot�erapy and� in case o� �ein� necessary� �ound-
Fig. 1. Concentration o� SO� in t�e di��erent sta�es o� t�e study. Middle sta�e 
2.25U/ml ± 1.30 vs. initial stage 0.73 U/ml±0.42   and final stage 1.67 U/ml ±0.94. 
(*) p <0�01.
Fig. 2. Concentration o� U� in t�e di��erent sta�es o� t�e study.   Middle sta�e 
1,17mg/dl ±0,22 vs.  initial stage 2,28 mg/dl±0,5 and final stage 1,58mg/dl ±0.33. (**) 
p<0.001.  
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in� new t�erapies usin� antioxidant supple�entation or 
nutritional prescriptions t�at �i��t elevate antioxidant 
local and syste�ic de�ences in BMT patients. 
Conclusions
T�e deter�ination o� t�e salivary concentrations o� anti-
oxidants suc� as SO� and U� provides a non-invasive 
�et�od w�ic� allows evaluatin� t�e de�ensive capacity 
o� t�e oral �ucosa in oncolo�ic patients under treat�ent 
wit� c�e�ot�erapy dru�s at �i�� doses.  
�t t�is study� t�e increase o� t�e levels o� SO� in pa-
tients t�at developed �ucositis could �e interpreted as 
a de�ense �ec�anis� in t�e presence o� t�e injury t�at 
c�e�ot�erapy represents to t�e cells o� t�e oral �ucosa� 
w�ile a decrease o� U� would allow t�e startin�� pro-
�ression and t�e tissue da�a�e. 
By virtue o� t�e results o�tained� we consider t�at it is 
necessary to do �uture researc� w�ic� per�it to o�tain 
�urt�er knowled�e a�out t�ese and ot�er antioxidant su�-
stances in saliva and its correlation wit� oral �ucositis.
T�e inte�ration o� dentists in t�e oncolo�y tea� �e-
co�es i�portant in t�e study� prevention� dia�no-
sis and treat�ent o� t�e oral co�plications� in order 
to i�prove t�e quality o� li�e in patients under�oin� 
c�e�ot�erapy.
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